TheraRadar
Data updated: May 26, 2026

BENZTROPINE MESYLATE

CNS Approved 1985-04-11

Benztropine mesylate is indicated as an adjunct therapy for all forms of parkinsonism. It is also used to control extrapyramidal disorders (excluding tardive dyskinesia) resulting from neuroleptic drug therapy, such as phenothiazines. The medication serves as a supplemental treatment to improve motor control and reduce symptoms such as tremors and rigidity.

Source: FDA Label • LANNETT CO INC

How BENZTROPINE MESYLATE Works

Benztropine mesylate is a centrally acting agent that possesses both anticholinergic (antimuscarinic) and antihistaminic effects. It acts as a competitive antagonist at muscarinic acetylcholine receptors in the corpus striatum. By blocking these receptors, it helps restore the functional balance between cholinergic and dopaminergic neurotransmission, which is disrupted in parkinsonism and drug-induced extrapyramidal reactions.

Source: FDA Label
15
Indications
--
Phase 3 Trials
41
Years on Market

BENZTROPINE MESYLATE Approval History

1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
201 FDA actions from 1985 to 2025
Feb 2025 ORIGINAL
Update
Aug 2024 SUPPL
Mfg · Manufacturing (CMC)
Jul 2023 SUPPL
Label · Labeling

What BENZTROPINE MESYLATE Treats

2 indications

BENZTROPINE MESYLATE is approved for 2 conditions since its original approval in 1985. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Parkinsonism
  • Extrapyramidal Disorder
Source: FDA Label

BENZTROPINE MESYLATE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to BENZTROPINE MESYLATE

3 of 7

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMANTADINE HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE
1 shared
Teva
Shared indications:
Parkinsonism
CREXONT
CARBIDOPA
1 shared
IMPAX
Shared indications:
Parkinsonism
DHIVY
CARBIDOPA
1 shared
AVION PHARMS
Shared indications:
Parkinsonism
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BENZTROPINE MESYLATE FDA Label Details

Indications & Usage

BENZTROPINE MESYLATE is indicated for the treatment of Parkinsonism; Extrapyramidal Disorder.

Looking for the branded version?

COGENTIN

Full clinical data, patents, trials, and competitive landscape for benztropine mesylate.

See COGENTIN

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.